Tgf-beta1 Smad
Tgf-beta1 Smad - Related Videos
02:40
Detecting SMAD Pathway Activation Using Dual Adenovirus Transduction
0 Views •
2026
Source: Chen, H., et al. Live Cell Imaging of the TGF-β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System. J. Vis. Exp. (2018).This video demonstrates a method to study SMAD pathway activation in breast cancer cells using dual adenoviral infection. One virus delivers a constitutively expressed GFP gene, while the other carries an RFP reporter under a SMAD-sensitive promoter. Upon TGF-beta stimulation, SMAD proteins are activated, forming a complex that induces RFP...
09:18
Spheroid Assay to Measure TGF-β-induced Invasion
0 Views •
Cited by 40 •
2011
An assay to quantitatively measure Transforming Growth Factor (TGF)-β-induced invasion in 3-dimensional collagen gels is described. This assay takes advantage of the MCF10A series of cell lines, which represent different stages of breast cancer development. This method can be adopted to be used with other cell lines and might be used to investigate other potential activators or inhibitors of invasion.
01:16
TGF - β Signaling Pathway
0 Views •
2023
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
06:54
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
0 Views •
Cited by 21 •
2020
We describe a systematic workflow to investigate TGF-β signaling and TGF-β-induced EMT by studying the protein and gene expression involved in this signaling pathway. The methods include Western blotting, a luciferase reporter assay, qPCR, and immunofluorescence staining.
08:20
In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
0 Views •
Cited by 26 •
2016
This protocol describes the reproducible generation and phenotyping of human induced regulatory T cells (iTregs) from naïve CD4+ T cells in vitro. Different protocols for FOXP3 induction allow for the study of specific iTreg phenotypes obtained with respective protocols.
FAQs
The signaling sequence begins when TGF-beta1 engages type II and type I serine/threonine kinase receptors. This receptor interaction leads to phosphorylation of Smad2 and Smad3, a regulatory modification that enables them to associate with Smad4. The resulting complex enters the nucleus, where it influences target-gene expression and connects extracellular signals with cellular responses.
Smad2 and Smad3 act as the signal-responsive proteins phosphorylated after receptor activation, whereas Smad4 joins them to form a nuclear regulatory complex. Smad7 has an opposing role because it can inhibit the pathway. This balance between signal transmission and inhibition helps determine how strongly TGF-beta1-related gene regulation affects cell behavior.
Abnormal activity can shift a pathway involved in tissue repair and immunity toward disease-associated effects. The overview links dysregulated TGF-beta1 Smad signaling with fibrosis, cancer progression, and inflammatory disorders. Studying these changes helps explain how altered gene regulation may contribute to pathological tissue responses and provides a basis for investigating disease mechanisms.
Investigating the pathway can connect receptor activation, Smad complex formation, nuclear entry, and target-gene control with clinically relevant disease processes. In medicine, this information supports research into mechanisms underlying fibrosis, cancer progression, and inflammatory disorders. It can also help researchers evaluate whether pathway-related changes may serve as biomarkers or therapeutic targets.
The main medical contexts identified are fibrosis, cancer progression, and inflammatory disorders. The pathway is also relevant to tissue repair and immunity, so research can examine how a normally important regulatory system becomes associated with harmful outcomes. Comparing its activity across these contexts may clarify shared mechanisms as well as disease-specific effects.
The pathway provides a framework for exploring targeted therapies and biomarkers rather than prescribing a specific treatment or marker. Researchers can examine abnormal receptor-to-Smad signaling, altered nuclear gene regulation, or the inhibitory influence of Smad7 in disease settings. Such studies may improve understanding of pathology and guide the development of more focused medical strategies.